Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
CT screening for lung cancer: implication of lung biopsy recommendations.
Wagnetz U, Menezes RJ, Boerner S, Paul NS, Wagnetz D, Keshavjee S, Roberts HC.
AJR Am J Roentgenol. 2012 Feb;198(2):351-8.
Related citations
Dose Escalation and Feasibility Study of Amrubicin Combined With Cisplatin in Previously Untreated Patients With Advanced Non-small-cell Lung Cancer.
Yoshimura N, Kimura T, Mitsuoka S, Kyoh S, Tochino Y, Asai K, Ichimaru Y, Hirata K, Kudoh S.
Am J Clin Oncol. 2012 Jan 19. [Epub ahead of print]
Endogenous angiogenesis inhibitor blocks tumor growth via direct and indirect effects on tumor microenvironment.
Bourboulia D, Jensen-Taubman S, Rittler MR, Han HY, Chatterjee T, Wei B, Stetler-Stevenson WG.
Am J Pathol. 2011 Nov;179(5):2589-600. Epub 2011 Sep 18.
Signal transducer and activator of transcription 3 (Stat3C) promotes myeloid-derived suppressor cell expansion and immune suppression during lung tumorigenesis.
Wu L, Du H, Li Y, Qu P, Yan C.
Am J Pathol. 2011 Oct;179(4):2131-41. Epub 2011 Aug 22.
Human immunodeficiency virus infection as a prognostic factor in surgical patients with non-small cell lung cancer.
Hooker CM, Meguid RA, Hulbert A, Taylor JT, Shin J, Wrangle J, Rodgers K, Lee B, Laskshmanan S, Brown T, Meneshian A, Sussman M, Keruly J, Moore RD, Yang SC, Brock MV.
Ann Thorac Surg. 2012 Feb;93(2):405-12.
Contribution of cell blocks obtained through endobronchial ultrasound-guided transbronchial needle aspiration to the diagnosis of lung cancer.
Sanz-Santos J, Serra P, Andreo F, Llatjós M, Castellà E, Monsó E.
BMC Cancer. 2012 Jan 21;12:34. doi: 10.1186/1471-2407-12-34.
Risk factors associated with fatal pulmonary hemorrhage in locally advanced non-small cell lung cancer treated with chemoradiotherapy.
Ito M, Niho S, Nihei K, Yoh K, Ohmatsu H, Ohe Y.
BMC Cancer. 2012 Jan 20;12:27.
A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer.
Kobayashi T, Koizumi T, Agatsuma T, Yasuo M, Tsushima K, Kubo K, Eda S, Kuraishi H, Koyama S, Hachiya T, Ohura N.
Cancer Chemother Pharmacol. 2012 May;69(5):1241-6. Epub 2012 Jan 26.
Glucose-regulated protein 58 modulates cell invasiveness and serves as a prognostic marker for cervical cancer.
Liao CJ, Wu TI, Huang YH, Chang TC, Wang CS, Tsai MM, Lai CH, Liang Y, Jung SM, Lin KH.
Cancer Sci. 2011 Dec;102(12):2255-63. doi: 10.1111/j.1349-7006.2011.02102.x. Epub 2011 Oct 17.
Asbestos surface provides a niche for oxidative modification.
Nagai H, Ishihara T, Lee WH, Ohara H, Okazaki Y, Okawa K, Toyokuni S.
Cancer Sci. 2011 Dec;102(12):2118-25. doi: 10.1111/j.1349-7006.2011.02087.x. Epub 2011 Sep 27.
Combined MEK and VEGFR inhibition in orthotopic human lung cancer models results in enhanced inhibition of tumor angiogenesis, growth, and metastasis.
Takahashi O, Komaki R, Smith PD, Jürgensmeier JM, Ryan A, Bekele BN, Wistuba II, Jacoby JJ, Korshunova MV, Biernacka A, Erez B, Hosho K, Herbst RS, O'Reilly MS.
Clin Cancer Res. 2012 Mar 15;18(6):1641-54. Epub 2012 Jan 24.
High EGFR gene copy number and skin rash as predictive markers for EGFR tyrosine kinase inhibitors in patients with advanced squamous cell lung carcinoma.
Lee Y, Shim HS, Park MS, Kim JH, Ha SJ, Kim SH, Cho BC.
Clin Cancer Res. 2012 Mar 15;18(6):1760-8. Epub 2012 Jan 23.
DNA methylation profiling defines clinically relevant biological subsets of non-small cell lung cancer.
Walter K, Holcomb T, Januario T, Du P, Evangelista M, Kartha N, Iniguez L, Soriano R, Huw L, Stern H, Modrusan Z, Seshagiri S, Hampton GM, Amler LC, Bourgon R, Yauch RL, Shames DS.
Clin Cancer Res. 2012 Apr 15;18(8):2360-73. Epub 2012 Jan 19.
Using patient-initiated study participation in the development of evidence for personalized cancer therapy.
Ambrose LF, Freedman J, Buetow K, Friend S, Schilsky RL.
Clin Cancer Res. 2011 Nov 1;17(21):6651-7.
Telomerase peptide vaccination in NSCLC: a phase II trial in stage III patients vaccinated after chemoradiotherapy and an 8-year update on a phase I/II trial.
Brunsvig PF, Kyte JA, Kersten C, Sundstrøm S, Møller M, Nyakas M, Hansen GL, Gaudernack G, Aamdal S.
Clin Cancer Res. 2011 Nov 1;17(21):6847-57. Epub 2011 Sep 14.
Pemetrexed Therapy in Elderly Patients With Good Performance Status: Analysis of Two Phase III Trials of Patients With Nonsquamous Non-Small-Cell Lung Cancer.
Gridelli C, Brodowicz T, Langer CJ, Peterson P, Islam M, Guba SC, Moore P, Visseren-Grul CM, Scagliotti G.
Clin Lung Cancer. 2012 Jan 20. [Epub ahead of print]
Phase I and II Trials of Vinorelbine With Carboplatin for Patients 75 Years of Age or Older With Previously Untreated Non-Small-Cell Lung Cancer.
Takatani H, Nakamura Y, Nagashima S, Soda H, Kinoshita A, Fukuda M, Fukuda M, Soejima Y, Kasai T, Nakatomi K, Iida T, Oka M, Tsukamoto K, Kohno S.
Clin Lung Cancer. 2012 Jan 18. [Epub ahead of print]
Proton Therapy With Concurrent Chemotherapy for Non-small-cell Lung Cancer: Technique and Early Results.
Hoppe BS, Flampouri S, Henderson RH, Pham D, Bajwa AA, D'Agostino H, Huh SN, Li Z, Mendenhall NP, Nichols RC.
Delay Between the Initial Symptoms, the Diagnosis and the Onset of Specific Treatment in Elderly Patients With Lung Cancer.
Giroux Leprieur E, Labrune S, Giraud V, Gendry T, Cobarzan D, Chinet T.
Metabolic pattern of glomic tumor by F-18 FDG PET/CT.
de Marco L, Mamede M.
Clin Nucl Med. 2011 Nov;36(11):1051-2. No abstract available.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on